Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis

Bibliography

• Du Pasquier RA, Pinschewer DD, Merkler D. Immunological mechanism of action of clinical profile of disease-modifying treatments in multiple sclerosis. CNS Drugs 2014;28:535-58
   PubMed Web of Science ®Google Scholar
• Wiendl H, Toyka KV, Rieckmann P. Multiple sclerosis therapy consensus group. basic and escalating immunomodulatory treatments in multiple sclerosis current therapeutic recommendations. J Neurol 2008;255:1149-63
   Google Scholar
• Johnson KP. Glatiramer acetate for treatment relapsing-remitting multiple sclerosis. Expert Rev Neurother 2012;12:371-84
   PubMed Web of Science ®Google Scholar
• Karussis D. Immunotherapy of multiple sclerosis: the state of the art. Bio Drugs 2013;113:48
   Google Scholar
• Astrom KE, Mancall EL, Richardson Jr EP. Progressive multifocal leuko-encephalopathy: a hithero unrecognized complication of chronic lymphatic leukaemia and Hodgkin’s disease. Brain 1958;81:93-111
   PubMed Web of Science ®Google Scholar
• Vennegoor A, van Rossum JA, Polman CH, et al. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy. Mult Scler 2015. [Epub ahead of print]
   Web of Science ®Google Scholar
• Calic Z, Cappelen-Smith C, Hodgkinson SJ, et al. Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab. J Clin Neurosci 2015;22:598-600
   PubMed Web of Science ®Google Scholar
• Keene DL, Legare C, Taylor E, et al. Monoclonal antibodies and progressive multifocal leukoecephalopathy. Can J Neurol Sci 2011;38:565-71
   PubMed Web of Science ®Google Scholar
• Antonsson A, Green AC, Mallitt KA, et al. Prevalence and stability of antibodies to the BK and JC polyomaviruses: a long-term longitudinal study of Australians. J Gen Virol 2010;91:1849-53
   PubMed Web of Science ®Google Scholar
• Viscidi RP, Rollison DE, Sondak VK, et al. Age-specific seroprevalence of Merkel cell polyomavirus, BK virus, and JC virus. Clin Vaccine Immunol 2011;18:1737-43
   PubMed Web of Science ®Google Scholar
• Seth P, Diaz F, Major E. Advances in the biology of JC virus and induction of progressive multifocal leukoencephalopathy. J Neuro Virol 2003;9:236-46
   PubMed Web of Science ®Google Scholar
• Tan CS, Ellis LC, Wuthrich C, et al. JC virus latency in the brain and extraneural organs of patients with and without progressive multifocal leukoencephalopathy. J Virol 2010;84:9200-9
   PubMed Web of Science ®Google Scholar
• Carruthers RL, Berger J. Progressive multifocal leukoencephalopathy and JC virus-related disease in modern neurology practice. Mult Scler Relat Disord 2014;3:419-30
   Google Scholar
• Chapagain ML, Nerurkar VR. Human polyomavirus JC (JCV) infection of human B lymphocytes: a possible mechanism for JCV transmigration across the blood-brain barrier. J Infect Dis 2010;202:184-91
   PubMed Web of Science ®Google Scholar
• Dubois V, Durtonic H, Lafon M, et al. Latency and reactivation of JC virus in peripheral blood of human immunodeficiency virus type1-infected patients. J Clin Microbiol 1997;35:2288-92
   PubMed Web of Science ®Google Scholar
• Dong-Si T, Richman S, Wattjes MP, et al. Outcome and survival of asymptomatic PML in natalizumab-treated MS patients. Ann Clin Transl Neurol 2014;1:755-64
   PubMed Web of Science ®Google Scholar
• Chalkey JJ, Bergen JR. Progressive multifocal leukoencephalopathy in multiple sclerosis. Curr Neurol Neurosci Rep 2013;13:408
   PubMed Web of Science ®Google Scholar
• Clifford D, DeLuca A, Simpson D, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010;9:438-46
   PubMed Web of Science ®Google Scholar
• Bloomgren G, Richman S, Hotermans et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366:1870-80
   PubMed Web of Science ®Google Scholar
• Vermersch P, Kappos I, Gold R, et al. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology 2011;76:1697-704
   PubMed Web of Science ®Google Scholar
• Tan K, Roda R, Ostrow I, et al. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 2009;72:1458-64
   PubMed Web of Science ®Google Scholar
• Dong-Si T, Gheuens S, Gangadharan A, et al. Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy. J Neurovirol 2015. [Epub ahead of print]
   PubMedGoogle Scholar
• Sheremata W, Brown AD, Rammohan KW. Dimethyl fumarate for treating relapsing multiple sclerosis. Expert Opin Drug Saf 2015;14:161-70
   PubMed Web of Science ®Google Scholar
• Kleinschmidt-Demasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353(4):369-74
   PubMed Web of Science ®Google Scholar
• Langer-Gould A, Atals SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353:375-81
   PubMed Web of Science ®Google Scholar
• Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placecontrolled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
   PubMed Web of Science ®Google Scholar
• McFarland H, Jacobson S. Natalizumab and immune cells. Arch Neurol 2006;63:1366-7
   PubMed Web of Science ®Google Scholar
• Stuve O, Marra C, Jerome K, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006;59:743-7
   PubMed Web of Science ®Google Scholar
• Rice GP, Hartung HP, Calabresi PA. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 2005;64:1336-42
   PubMed Web of Science ®Google Scholar
• Stuve O, Marra CM, Bar-Or A, et al. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol 2006;63:1383-7
   PubMed Web of Science ®Google Scholar
• Chen Y, Bord E, Tomkins T, et al. High incidence of JC viruria in JC-seropositive older individuals. J Neurovirol 2002;8:447-51
   PubMed Web of Science ®Google Scholar
• Warnke C, Menge T, Hartung HP, et al. Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors? Can it be avoided? Arch Neurol 2010;67:923-30
   PubMed Web of Science ®Google Scholar
• Bennett JL. Natalizumab and progressive multifocal leukoencephalopathy: migrating towares safe adhesion molecule therapy in multiple sclerosis. Neurol Res 2006;28:291-8
   PubMed Web of Science ®Google Scholar
• Ransohoff RM. Natalizumab and PML. Nat Neurosci 2005;8:1275
   PubMed Web of Science ®Google Scholar
• Bloomgren D, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366:1870-80
   PubMed Web of Science ®Google Scholar
• Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 2010;33:91-101
   PubMed Web of Science ®Google Scholar
• Williamson EM, Berger JR. Infection risk in patients on multiple sclerosis therapies. CNS Drugs 2015;29:229-44
   PubMed Web of Science ®Google Scholar
• Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 2010;33:91-101
   PubMed Web of Science ®Google Scholar
• Killestein J, Vennegoor A, van Golde AEL, et al. PML-IRIS during fingolimod diagnosed after natalizumab discontinuation. Case Rep Neurol Med 2014;2014:307872
   PubMedGoogle Scholar
• Putzki N, Clifford DB, Bischof D, et al. Characteristics of PML cases in multiple sclerosis patients switching to fingolimod from natalizumab. Presented at. Joint ACTRIMS-ECTRIMS Meeting; Boston, MA, 2014. Available from: http://msj.sagepub.com/content/20/1_suppl/14.full.pdf+html. [ Last accessed 8 July 2015]
   Google Scholar
• Safety Announcement. FDA drug safety communication: FDA investigating rare brain infection in patient taking Gilenya (fingolimod). Available from: www.fda.gov/Drugs/DrugSafety/ucm366529.htm [Last accessed 8 July 2015]
   Google Scholar
• Novartis Pharmaceuticals. Fingolimod (Gilenya): first reported case of progressive multifocal leukoencephalopathy (PML) in a multiple sclerosis patient taking Fingolimod without previous treatment by natalizumab or other immunosuppressive medicines. 9 April 2015. (Letter). Available from: www.hpra.ie/docs/default-source/default-document-library/hpra-letter-gilenya-09-april-2015.pdf?sfvrsn=0 [Last accessed 8 July 2015]
   Google Scholar
• Novarits Pharmaceuticals. Gilenya Safety Update. 5 June 2015. Available from: www.novartis.com/news/statements/gilenya-safety-update [Last accessed 8 July 2015]
   Google Scholar
• Novartis Pharmaceuticals. Gilenya Information Center. 17 Aug 2015. Available from: www.novartis.com/news/statements/gilenya-information-center [Last accessed 28 Aug 2015]
   Google Scholar
• Linker RA, Lee DH, Ryan S, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation vis activation of the Nrf2 antioxidant pathway. Brain 2011;134:678-92
   PubMed Web of Science ®Google Scholar
• Scannervin RH, Chollate S, Jung MY, et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like2 pathway. J Pharmacol Exp Ther 2012;341:274-84
   PubMed Web of Science ®Google Scholar
• van Oosten BW, Killestein J, Barkhof F, et al. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med 2013;368:1658-9
   PubMed Web of Science ®Google Scholar
• Nieuwkamp DJ, Murk JL, van Oosten BW. PML in a patient without severe lymphocytopenia receiving dimethyl fumarate. N Engl J Med 2015;372(15):1474-6
   PubMed Web of Science ®Google Scholar
• Sweetser MT, Dawson KT, Bozic C. Manufacturer’s response to case reports of PML. N Engl J Med 2013;368(17):1659-61
   PubMed Web of Science ®Google Scholar
• Rosendranz T, Novas M, Terborg C. PML in a patient with lymphocytopenia treated with dimethyl fumarate. N Engl J Med 2015;372(15):1476-8
   PubMed Web of Science ®Google Scholar
• da Silva Nali LH, Moraes L, Domingues Fink MC, et al. Natalizumab treatment for multiple sclerosis: updates and considerations for safer treatment in JCV positive patients. Arq Neuropsiquiatr 2014;72(12):960-5
   PubMed Web of Science ®Google Scholar
• Xia MQ, Hale G, Lifely MR, et al. Structure of the CAMPATH-1 antigen, a glycosylphophatidylinoitol-anchored glycoprotein which is an exceptionally good tartet for complement lysis. Biochem J 1993;293:633-40
   PubMed Web of Science ®Google Scholar
• Isidoro L, Pires P, Rito L, et al. Progressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukemia treated with alemtuzumab. BMJ Case Rep 2014;12:164-79
   Google Scholar
• Uppenkamp M, Engert A, Diehl V, et al. Monoclonal antibody therapy with CAMPATH-1H in patients with relapse high- and low-grade non-Hodgkin’s lymphomas: a multicenter phase I/II study. Ann Hematol 2002;81:26-32
   PubMed Web of Science ®Google Scholar
• Martin SI, Marty FM, Fiumara K, et al. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. CID 2006;43:16-24
   PubMed Web of Science ®Google Scholar
• D’Souza A, Wilson J, Mukherjee S, et al. Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia: a report of three cases and review of the literature. Clin Lymphoma Myeloma Leuk 2010;4:e2012043
   Google Scholar
• He D, Guo R, Zhang F, et al. The Cochrane Database Of Systematic Reviews [Cochrane Database Syst Rev], ISSN: 1469-493X, 2013 Dec 06; Vol 12; Publisher: Wiley; Cochrane AN: CD009130; PMID: 24310855
   Google Scholar
• Castillo-Trivino T, Braithwaite D, Bacchetti P, et al. Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review. PLoS One 2013;8(7):e66308
   PubMed Web of Science ®Google Scholar
• Zahir F, Berger JR. Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps. Ther Adv Drug Saf 2012;3(5):227-39
   Google Scholar
• Asztely F, Gilland E, Wattjes MP, et al. Rituximab treatment did not aggravate ongoing progressive multifocal leukoencephalopathy in a patient with multiple sclerosis. J Neurol Sci 2015;353(1-2):155-7
   PubMed Web of Science ®Google Scholar
• Lee P, Plavina T, Castro A, et al. A second-generation ELISA (STRATIFY JCVTM DxSelectTM) for detection of JC virus antibodies in human serum and plasma to support a progressive multifocal leukoencephalopathy risk stratification. J Clin Virol 2013;57(2):141-6
   PubMed Web of Science ®Google Scholar
• Warnke C, Ramanujam R, Plavina T, et al. Changes to anti-JCV antibody levels in a Swedish national MS cohort. J Neurol Neurosurg Psychiatry 2013;84:199-205
   Google Scholar
• Trampe AK, Hemmelmann C, Stroet A, et al. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology 2012;78:1736-42
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 2012;18:143-52
   PubMed Web of Science ®Google Scholar
• Rossi F, Newsome SD, Viscidi R. Molecular diagnostic tests to predict the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients. Mol Cell Probes 2015;29(1):54-62
   PubMed Web of Science ®Google Scholar
• Antonial C, Stankoff B. Immunological markers for PML prediction in MS patients treated with natalizumab. Front Immunol 2015;5:668
   Google Scholar
• Bozic C, Subramanyam M, Richman S, et al. Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial. Eur J Neurol 2014;21(2):299-304
   PubMed Web of Science ®Google Scholar
• Bozic C, Richman S, Plavina T, et al. Anti-John Cunningham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol 2011;70:742-50
   PubMed Web of Science ®Google Scholar
• Plavina T, Subramanyam M, Bloomgren G, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2014;76:802-12
   PubMed Web of Science ®Google Scholar
• Mc Govern EM, Hennessy MJ. Asymptomatic progressive multifocal leukoencephalopathy associated with natalizumab. J Neurol 2013;260:665-7
   PubMed Web of Science ®Google Scholar
• Phan-Ba R, Lommers E, Tshibanda L, et al. MRI preclinical detection and asymptomatic course of a progressive multifocal leukoencephalopathy (PML) under natalizumab therapy. J Neurol Neurosurg Psychiatry 2012;83:224-6
   PubMed Web of Science ®Google Scholar
• Wattjes MP, Vennegoor A, Steenwijk MD, et al. MRI pattern in asymptomatic natalizumab-associated PML. J Neurol Neurosurg Psychiatry 2015;86(7):793-8
   PubMed Web of Science ®Google Scholar
• Ferrè L, Moiola L, Sangalli F, et al. Recurrence of disease activity after repeated natalizumab withdrawals. Neurol Sci 2015;36:465-7
   PubMed Web of Science ®Google Scholar
• Du Pasquier RA, Pinschewer DD. Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis. CNS Drugs 2014;28:535-58
   PubMed Web of Science ®Google Scholar
• Prosperini L, Annovazzi P, Capobianco M, et al. Natalizumab discontinuation in patients with multiple sclerosis: profiling risk and benefits at therapeutic crossroads. Mult Scler 2015. [Epub ahead of print]
   Web of Science ®Google Scholar
• Giovannoni G, Naismith RT. Natalizumab to fingolimod washout in patients at risk of PML. When good intentions yield bad outcomes. Neurology 2014;82(14):1196-7
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, Comi G, et al. Disease control and safety in relapsing remitting multiple sclerosis (RRMS) patients switching from natalizumab to fingolimod: a 32-week, rater- and patient-blind, randomized, parallel-group study. Mult Scler 2013;19(S1):50
   Google Scholar
• Jelcic I, Jelcic I, Faigle W, et al. Immunology of progressive multifocal leukoencephalopathy. J Neurovirol 2015. [Epub ahead of print]
   PubMedGoogle Scholar
• Vennegoor A, Rispens T, van Oosten BW, et al. Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy. Mult Scler 2015;21(4):481-4
   PubMed Web of Science ®Google Scholar
• Tan IL, McArthur JC, Clifford DB, et al. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology 2011;77:1061-7
   PubMed Web of Science ®Google Scholar
• Lalive PH, Bridel C, Ferfoglia RI, et al. Minimal supportive treatment in natalizumab-related PML in a MS patient. J Neurol Neurosurg Psychiatry 2015;86(3):354-5
   PubMed Web of Science ®Google Scholar
• Antoniol C, Jilek S, Schluep M, et al. Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management? Neurology 2012;79:2258-64
   PubMed Web of Science ®Google Scholar
• Clifford D, Nath A, Cinque P, et al. Mefloquine Treatment in Patients with Progressive Multifocal Leukoencephalopathy. Neurology 2011;76:A28
   PubMed Web of Science ®Google Scholar
• Cettomai D, McArthur JC. Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy. Arch Neurol 2009;66(2):255-8
   PubMed Web of Science ®Google Scholar
• Martin-Blondel G, Cuzin L, Delobel P, et al. Is maraviroc beneficial in paradoxical progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome management? AIDS 2009;23(18):2545-6
   PubMed Web of Science ®Google Scholar
• Stork L, Brück W, Bar-Or A, et al. High CCR5 expression in natalizumab-associated progressive multifocal leukoencephalopathy immune reconstitution inflammatory syndrome supports treatment with the CCR5 inhibitor maraviroc. Acta Neuropathol 2015;129:467-8
   PubMed Web of Science ®Google Scholar